Xiansheng Pharmaceutical (02096) spent HK$781,600 to buy back 138,000 shares on May 3
According to the Zhitong Finance App, Xiansheng Pharmaceutical (02096) announced that on May 3, 2024, the company spent HK$781,600 to repurchase 138,000 shares at a repurchase price of HK$5.64-5.67 per share.
CSPC Group (01093.HK) cancelled 26.628 million shares on May 3
Gelonghui, May 3, 丨 Shiyao Group (01093.HK) announced that on May 3, 2024, 26.628 million shares have been cancelled.
CCB International: Maintaining Cinda Biotech's (01801) “Outperform the Market” rating and raising the target price to HK$54.7
According to CCB International, Cinda Biotech (01801) is one of the bank's preferred stocks in the Chinese pharmaceutical industry.
Changes in Hong Kong stocks | CRO concept stocks fell across the board, Yakming Kangde (02359) fell more than 7%, leading the decline, and the company's profit margin for the first quarter fell short of expectations
CRO concept stocks fell across the board. As of press release, Yao Ming Kangde (02359) fell 6.47% to 36.15 yuan; Gloria Ying (06821) fell 5.33% to 63.05 yuan; Kanglong Chemical (03759) fell 4.96% to HK$9.96.
Hong Kong Stock Concept Tracking | China's Nuclear Medicine Industry Attracts Attention (with concept stocks), the key technology for batch online irradiation production of isotopes
Various short-half-life medical isotopes that are currently in short supply in China will enter the large-scale production stage after the supporting plant is completed and put into operation in the second half of this year.
YiChang HEC ChangJiang Pharmaceutical's (HKG:1558) Earnings May Just Be The Starting Point
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) strong earnings report was rewarded with a positive stock price move. Our analysis found some more factors that we think are good for shar